The collaboration will combine Magenta's stem cell platform with proprietary antibodies across up to four exclusive targets with Heidelberg Pharma's proprietary antibody targeted amanitin conjugates (ATAC) platform.
Under the terms of the multi-target research agreement, Magenta will have access to Heidelberg Pharma's Amanitin toxin-linker platform technology. Magenta has an option for an exclusive target-specific license for global development and commercialization rights to each of the product candidates resulting from the research collaboration.
Heidelberg Pharma will receive upfront technology access and exclusivity fees and payments for research support.
Under the exclusive license agreement, Heidelberg Pharma would be eligible to receive option fees, clinical development, regulatory and sales-related milestone payments up to USD334 m, if Magenta exercises all target options and all milestones are met.
Magenta Therapeutics is developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers, and genetic diseases.
By creating a platform focused on critical areas of transplant medicine, the company is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients.
Heidelberg Pharma developed the toxin Amanitin into cancer therapies using its proprietary ATAC technology and advanced the biological mode of action of the toxin as a novel therapeutic principle.
This proprietary technology platform is being applied to develop the company's proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial